Zhejiang Jingxin Pharmaceutical's financial performance remains strong with above-average ROE and successful reinvestment of profits. The company's promising earnings growth track is expected to continue.
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more